MFDS Engages in Discussions with U.S. FDA for Activation of AI Medical Products
AI Medical |
The MFDS and the U.S. FDA will host the AI Regulatory & International Symposium (AIRIS) 2024 from February 26 to 29. Over the course of four days, regulatory authorities and experts from around the world have been invited to discuss "Utilizing Artificial Intelligence (AI) for the Advancement of Medical Products.
At this AIRIS 2024, discussions will take place on the global trends, technical aspects, and application cases of AI in the advancement of medical products. Additionally, experts will share regulatory experiences related to this field and present their insights into the future.
On the final day of the symposium, a regulatory agency participation meeting session is also prepared to discuss 'Regulatory Considerations and International Collaboration Strategies for the Utilization of AI in the Advancement of Medical Products.'
The MFDS expressed anticipation for active discussions with participants, including the U.S. FDA, during this symposium regarding the use of emerging technologies for the supply of safe and effective medical products. They also highlighted the hope for increased awareness among nations about the necessity of global collaboration to promote such innovations.
Comments
Post a Comment